These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

45 related articles for article (PubMed ID: 17956667)

  • 21. WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia.
    Roman-Gomez J; Jimenez-Velasco A; Cordeu L; Vilas-Zornoza A; San Jose-Eneriz E; Garate L; Castillejo JA; Martin V; Prosper F; Heiniger A; Torres A; Agirre X
    Eur J Cancer; 2007 Dec; 43(18):2736-46. PubMed ID: 18032022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Wnt5A/CaMKII signaling contributes to the inflammatory response of macrophages and is a target for the antiinflammatory action of activated protein C and interleukin-10.
    Pereira C; Schaer DJ; Bachli EB; Kurrer MO; Schoedon G
    Arterioscler Thromb Vasc Biol; 2008 Mar; 28(3):504-10. PubMed ID: 18174455
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Differentiation-inducing effects of perphenazine on K562 leukemia cells].
    Yuan LB; He Q
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Jun; 30(3):288-91. PubMed ID: 16045015
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Targeted blockage of RNA binding protein E2 by decoy RNA induces the granulocytic differentiation of K562 cells].
    Chen XM; Feng WL; Xu SX; Zeng JM; Zhao SQ; Luo HW; Bai WJ; Wang XZ; Huang ZG
    Zhonghua Xue Ye Xue Za Zhi; 2008 Jan; 29(1):34-8. PubMed ID: 18512313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. WNT5A exhibits tumor-suppressive activity through antagonizing the Wnt/beta-catenin signaling, and is frequently methylated in colorectal cancer.
    Ying J; Li H; Yu J; Ng KM; Poon FF; Wong SC; Chan AT; Sung JJ; Tao Q
    Clin Cancer Res; 2008 Jan; 14(1):55-61. PubMed ID: 18172252
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 9-(2-Phosphonylmethoxyethyl)adenine induces tumor cell differentiation or cell death by blocking cell cycle progression through the S phase.
    Hatse S; Schols D; De Clercq E; Balzarini J
    Cell Growth Differ; 1999 Jun; 10(6):435-46. PubMed ID: 10392905
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Induction of suppressive phenotype in monocyte-derived dendritic cells by leukemic cell products and IL-1β.
    Motta JM; Sperandio A; Castelo-Branco MT; Rumjanek VM
    Hum Immunol; 2014 Jul; 75(7):641-9. PubMed ID: 24768898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunohistochemical analysis of monocytic leukemias: usefulness of CD14 and Kruppel-like factor 4, a novel monocyte marker.
    Klco JM; Kulkarni S; Kreisel FH; Nguyen TD; Hassan A; Frater JL
    Am J Clin Pathol; 2011 May; 135(5):720-30. PubMed ID: 21502426
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Influence of celecoxib combined with IFN-alpha on proliferation, apoptosis, cell cycle and CD117 expression of K562 cells].
    Xie ZN; Liu DS; Cao WK; Deng ZK; Li YF
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Apr; 18(2):330-4. PubMed ID: 20416162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of Wnt proteins on cell proliferation and apoptosis in HEK293 cells.
    Jia L; Miao C; Cao Y; Duan EK
    Cell Biol Int; 2008 Jul; 32(7):807-13. PubMed ID: 18462958
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Wnt5a is required for proper epithelial-mesenchymal interactions in the uterus.
    Mericskay M; Kitajewski J; Sassoon D
    Development; 2004 May; 131(9):2061-72. PubMed ID: 15073149
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparative proteomics analysis on differentiation of human promyelocytic leukemia HL-60 cells into granulocyte and monocyte lineages.
    Wang WJ; Tang W; Qiu ZY
    Ai Zheng; 2009 Feb; 28(2):117-21. PubMed ID: 19550115
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Importance of P-cadherin, beta-catenin, and Wnt5a/frizzled for progression of melanocytic tumors and prognosis in cutaneous melanoma.
    Bachmann IM; Straume O; Puntervoll HE; Kalvenes MB; Akslen LA
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8606-14. PubMed ID: 16361544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reversible differentiation of human monoblastic leukemia U937 cells by ML-9, an inhibitor of myosin light chain kinase.
    Yamamoto-Yamaguchi Y; Makishima M; Kanatani Y; Kasukabe T; Honma Y
    Exp Hematol; 1996 May; 24(6):682-9. PubMed ID: 8635523
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Growth and differentiation effect on HL60 cells by adenovirus-mediated exogenous wnt5a gene modification on human bone marrow mesenchymal stem cells].
    Shen YL; Xu YH; Luo Q; Guo ZH; Zheng GH; Guo YX
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2010 Nov; 41(6):931-5. PubMed ID: 21265088
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [EGR-1 mRNA expression during 12-0-tetradecanoylphorbol-13-acetate-induced K562 cell differentiation].
    Fang DZ; Liao QK; Gao J; Yang XJ; Yuan LX; Jia GC
    Zhonghua Er Ke Za Zhi; 2004 Jul; 42(7):495-8. PubMed ID: 15324564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Wnt5a inhibits human monocyte-derived myeloid dendritic cell generation.
    Bergenfelz C; Janols H; Wullt M; Jirström K; Bredberg A; Leandersson K
    Scand J Immunol; 2013 Aug; 78(2):194-204. PubMed ID: 23679576
    [TBL] [Abstract][Full Text] [Related]  

  • 38. WNT5A expression is regulated by the status of its promoter methylation in leukaemia and can inhibit leukemic cell malignant proliferation.
    Deng G; Li ZQ; Zhao C; Yuan Y; Niu CC; Zhao C; Pan J; Si WK
    Oncol Rep; 2011 Feb; 25(2):367-76. PubMed ID: 21165581
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Differentiation phenotypes of k562 cells induced by exogenous wnt5a].
    Yuan Y; Si WK; Li ZQ; Pan J; Zhao C
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):946-9. PubMed ID: 17956667
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.